期刊文献+

非霍奇金淋巴瘤患者血浆内皮生长因子水平测定及临床意义

The Clinical Significance of Detecting Plasma Vascular Endothelial Growthfactor Concentration in Non-hodgkin's Lymphoma
下载PDF
导出
摘要 目的通过检测非霍奇金淋巴瘤(NHL)患者血浆中血管内皮生长因子(VEGF)水平,探讨其临床意义。方法应用双抗体夹心酶联免疫吸附测定法(ELISA)检测初治40例NHL患者和20例正常对照组血浆中VEGF含量。结果NHL患者VEGF水平明显高于对照组(P〈0.01),病变为Ⅲ~Ⅳ期、有纵隔浸润或腹部伴纵隔浸润患者血浆VEGF水平明显高于病变为Ⅰ~Ⅱ期、仅浅表淋巴结肿大患者(P〈0.01)。经治疗后达完全缓解的患者血浆VEGF水平下降至正常或接近正常,与治疗前相比,差异有显著性(P〈0.01),复发/进展者VEGF水平与治疗前相比,差异无显著性(P〉0.05)。结论血浆VEGF水平可反映体内淋巴瘤细胞的总负荷和疾病状态,测定血浆VEGF水平对NHL分期、病变部位的判断、疗效观察和预后具有一定临床意义。 Objective From detecting the VEGF levels in the plasma of NHL patients,to explore the clinical significance of the vascular endothelial growthfactor. Methods The plasma vascular endothelial growthfactor levels were detected in 40 cases of initial treatment non-Hodgkin's lymphoma patients and 20 normal control cases by double-antibody sandwich enzyme-linked immunosorbent assay way. Results Compared with normal control group the vascular endothelial growthfactor levels of non-Hodgkin's lymphoma patients were significantly higher( P 〈0.01 ). The plasma vascular endothelial growthfactor levels of the cases of Ⅲ - Ⅳstage or mediastinal infiltration invasion and abdomen with mediastinal or abdominal infiltration were significantly higher than the lesions of Ⅰ - Ⅲstage or only with superficial lymphadenectasis( P 〈 0.01 ). The vascular endothelial growthfactor levels of the complete remission patients were decreased to normal or near normat after treatment. There were significant differences compared with the levels before treatment( P 〈 0.01 ). There was no significant difference between recurrence or aggravation patients and the levels before treatment ( P 〉 0.05 ). Conclusion The plasma vascular endothelial growthfactor levels can reflect the vivo lymphoma cells overall load and morbid state. There were important clinical significance of detecting the plasma vascular endothelial growthfactor levels in the staging of non-Hodgkin 's lymphoma, the judgment of diseased region, pathogenetic condition, the observation of therapeutic effect and prognosis.
出处 《潍坊医学院学报》 2008年第3期244-245,共2页 Acta Academiae Medicinae Weifang
关键词 非霍奇金淋巴瘤 血管新生 血管内皮生长因子 Non-Hodgkin's lymphoma Angiogenesis Vascular endothelial growthfactor
  • 相关文献

参考文献5

  • 1Plouet J, Moro F, Bertagnolli S, et al. Extracellular cleavage of the vascularen do the lialg rowth factorl 89-aminoa cid form byu rokinasei sr equired fori tsmi to genicefect [ J]. J Biolc Hem,2002,272(20) :13 390 - 13 396.
  • 2张颢,陶艳玲,曾宪昌,张克俭.血管内皮生长因子在恶性血液病中的研究进展[J].四川肿瘤防治,2002,15(1):53-55. 被引量:5
  • 3张之南.血液病治疗及疗效标准[M].第2版,北京:科学出版社,1998:349-358.
  • 4Scott PA, Gleadle JM, Bicknell R, et al. Role of the hypoxia sensing-system, acidity and reproductive hormones in the variability of vascularendothelial growth factor induction in human breast carcinoma cell lines[ J ]. Int J Cancer, 1998,75 (9) :706 - 712.
  • 5Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysp lastic syndromes [ J ]. Blood, 2000, 96(25) :2 240-2 245.

二级参考文献19

  • 1[1]Neufeld G, Cohtn T, Hela GG, et al. Similarities and differences between the vascular endothelial growth factor(VEGF) splice variants[ J ] Cancer and Metastasis Reviews, 1996,15 : 153-158.
  • 2[2]Ferrara N, Davis, Smgth T, et al. The biology of vascular endothelial growth factor[J]. Endocr Res, 1997,18:4-25.
  • 3[3]Park J, Keller GA,Ferrara N, etal. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subeithelial extraceiluar matrix and bioactivity of extracellular maxtrix - bound VEGF[J]. Mol Biol Cell, 1993,4:1317.
  • 4[4]Kraft A, Weindel K, et al. Vascular endothelial growth factor in the sera and effusions of patients eith malignant and nonmalignant disease [J] .Cancer 1999,85(1) : 178.
  • 5[5]BelLamy WT, Righter L, Frutiger Y. etal. Expression ofvascular endothelial growth factor and its receptor in haematopoietic malignances [J]. Cancer Rse, 1999,92(2) :728-723.
  • 6[6]Padro T, Ruiz S, Bieker R, et al. Increased angiogensis in the bone marrow of patients with acute myeloid Leukemia [J]. Blood, 2000, 95 : 2637-2644.
  • 7[7]Amcet R, Kinl Lo, Aune C, et al. Angiogenesis in acute promyelocyrie leukemia induction by vascular endothelial growth factor and inhihitien by all- trans retinoie acid[J]. Blood,2001,97:3919-3924.
  • 8[8]Bairey V,Zimra Y,Shaklai M,et al. BCL-2 expression-correlates positively with serum basic fibroblest growth factor(bFGF) and negatively with cellular vnsenlar endothelial growth factor (VEGF)in patients with chronic lymphocytic leukemia[J]. Br J Hematology, 2001,113 :400-406.
  • 9[9]Aghago A, Brien S, Kentiug M, et al. Clinical relevance of intra cllenlar vascular endothelial growth factor levels in B-cell chrenie lymphoeyrie lenkemia[J]. Blond,2000,96:768-770.
  • 10[10]MolieaS, Vitelli G, Levato D, et al.lnereased serum levels of vnsenlar endothelial growth factor predict fish of progression in early B-cell chronic lymphocytic lenkemia[J]. Br J Hematology, 1999,107:605-610.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部